In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Let me give you an example: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
The answer to this example can be: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Here is why: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

OK. solve this:
SECTION 1. SHORT TITLE.

This Act may be cited as the ''Mitochondrial Medicine Research and
Treatment Enhancement Act''.

SEC. 2. FINDINGS AND PURPOSE.

(a) Findings.--Congress finds the following:
(1) Mitochondrial disease results when there is a defect
that reduces the ability of the mitochondria in a cell to
produce energy. As the mitochondria fail to produce enough
energy, the cell will cease to function properly and will
eventually die. Organ systems will begin to fail, and the life
of the individual is compromised or ended.
(2) There are more than 40 specifically identified
mitochondrial diseases, but the vast majority have not yet been
identified.
(3) Mitochondrial diseases are a relatively newly diagnosed
group of diseases, first recognized in the late 1960s.
Diagnosis is extremely difficult for a number of reasons.
(4) Mitochondrial diseases can present themselves at any
age, with associated mortality rates that vary depending upon
the particular disease. The most severe diseases result in
progressive loss of neurological and liver function, and death
within several years.
(5) According to the National Institute of Environmental
Health Sciences, half of those affected by mitochondrial
disease are children, who show symptoms before age five and
approximately 80 percent of whom will not survive beyond the
age of 20.
(6) Mitochondrial dysfunction is also associated with
numerous other related disorders, including many common
neurological diseases (such as Parkinson's, Alzheimer's, ALS,
and autism), and other diseases associated with aging,
diabetes, cancer, and obesity.
(7) Mitochondrial disease is most commonly the result of
genetic mutation, either in the nuclear DNA or in the
mitochondrial DNA. Some mitochondrial diseases also are
attributable to environmental factors, including prescription
medications, that interfere with mitochondrial function.
(8) Researchers estimate that one in 4,000 children will
develop a mitochondrial disease related to an inherited
mutation by the age of 10 years, and that 1,000-2,000 children
are born each year in the United States who will develop
mitochondrial disease in their lifetimes. However, studies of
umbilical cord blood samples show that one in 200 children are
born with both normal and mutant mitochondrial DNA, and the
number of children with these mutations who actually develop a
disease is unknown.
(9) There are no cures for any of the specifically
identified mitochondrial diseases, nor is there a specific
treatment for any of these diseases.
(10) Improving our basic understanding of mitochondrial
function and dysfunction has potential application to numerous
areas of biomedical research. The National Institutes of Health
has taken an increased interest in mitochondrial disease and
dysfunction and has sponsored a number of activities in recent
years aimed at advancing mitochondrial medicine, including
incorporating research into functional variation in
mitochondria in the Transformative Research Grants Initiative.
(b) Purpose.--It is the purpose of this Act to promote an enhanced
research effort aimed at improved understanding of mitochondrial
disease and dysfunction and the development of treatments for
mitochondrial disease.

SEC. 3. ENHANCEMENT OF RESEARCH AND TREATMENT ACTIVITIES RELATED TO
MITOCHONDRIAL MEDICINE.

(a) Mitochondrial Medicine Research Enhancement.--Part A of title
IV of the Public Health Service Act (42 U.S.C. 281 et seq.) is
amended--
(1) by redesignating section 404H as section 404I; and
(2) inserting after section 404G the following new section:

''SEC. 404H. OFFICE OF MITOCHONDRIAL MEDICINE.

''(a) Establishment.--There is established within the Office of the
Director of NIH an office to be known as the Office of Mitochondrial
Medicine (in this section referred to as the 'Office'), which shall be
headed by a Director (in this section referred to as the 'Director'),
appointed by the Director of NIH.
''(b) Mitochondrial Medicine Research Plan.--
''(1) In general.--The Director shall develop, make
publicly available, and implement a written plan to facilitate
research into mitochondrial medicine.
''(2) Contents.--The plan required under paragraph (1)
shall include the following objectives:
''(A) Improving coordination of research related to
mitochondrial medicine among the national research
institutes and between the National Institutes of
Health and outside researchers.
''(B) Providing training to research scientists and
health professionals engaged in research related to
mitochondrial medicine.
''(C) Providing training to health care providers
regarding the diagnosis of mitochondrial disease and
dysfunction.
''(D) Establishing scientific review groups with
expertise in mitochondrial medicine to oversee relevant
research projects in the National Institutes of Health.
''(3) Consultation.--In developing the plan under paragraph
(1), the Director shall consult with--
''(A) the Director of the National Cancer
Institute;
''(B) the Director of the National Institute of
Child Health and Human Development;
''(C) the Director of the National Institute of
Environmental Health Sciences;
''(D) the Director of the National Heart, Lung, and
Blood Institute;
''(E) the Director of the National Institute of
Neurological Disorders and Stroke;
''(F) the Director of the National Institute of
Diabetes and Digestive and Kidney Diseases;
''(G) the Director of the National Eye Institute;
and
''(H) the heads of such other institutes and
offices as the Director considers appropriate.
''(4) Updates.--The Director shall update the plan required
under paragraph (1) on a biennial basis.
''(c) Research Grants.--In addition to any grants otherwise awarded
by the National Institutes of Health for research in mitochondrial
medicine, the Director shall annually award--
''(1) at least five grants for integrated, multi-project
research programs related to mitochondrial medicine; and
''(2) at least five grants for planning activities
associated with integrated, multi-project research programs
related to mitochondrial medicine.
''(d) Centers of Excellence.--
''(1) In general.--The Director may award grants to
institutions or consortiums of institutions to establish
Mitochondrial Medicine Centers of Excellence to promote
interdisciplinary research and training related to
mitochondrial medicine.
''(2) Use of funds awarded.--A grant awarded under
paragraph (1) shall be used to--
''(A) conduct basic and clinical research related
to mitochondrial medicine;
''(B) facilitate training programs for research
scientists and health professionals seeking to engage
in research related to mitochondrial medicine;
''(C) develop and disseminate programs and
materials to provide continuing education to health
care professionals regarding the recognition,
diagnosis, and treatment of mitochondrial disease and
dysfunction; and
''(D) provide living stipends for research
scientists and health professionals enrolled in
mitochondrial research training programs.
''(e) National Registry; Biorepository.--
''(1) National registry.--The Director shall establish a
national registry for the maintenance and sharing for research
purposes of medical information collected from patients with
mitochondrial disease or dysfunction.
''(2) Biorepository.--The Director shall establish a
national biorepository for the maintenance and sharing for
research purposes of tissues and DNA collected from patients
with mitochondrial disease or dysfunction.
''(f) Definition.--In this section, the term 'mitochondrial
medicine' means medical treatment related to mitochondrial disease or
dysfunction.''.
(b) Development of Mitochondrial Medicine Research Plan.--The
Director of the Office of Mitochondrial Medicine shall develop and make
publicly available the mitochondrial medicine research plan required
under section 404H(b)(1) of the Public Health Service Act, as added by
subsection (a) of this section, not later than 180 days after the date
of the enactment of this Act.
Answer:
Mitochondrial Medicine Research and Treatment Enhancement Act - Amends the Public Health Service Act to establish within the Office of the Director of the National Institutes of Health (NIH) an Office of Mitochondrial Medicine (OMM).

Requires the OMM Director to develop, make publicly available, implement, and biennially update a written plan to facilitate research into mitochondrial medicine. Sets forth as plan objectives: (1) improving coordination of research related to mitochondrial medicine among the national research institutes and between NIH and outside researchers; (2) providing training to research scientists and health professionals engaged in research related to mitochondrial medicine; (3) providing training to health care providers regarding the diagnosis of mitochondrial disease and dysfunction; and (4) establishing scientific review groups with expertise in mitochondrial medicine to oversee relevant research projects in NIH.

Requires the OMM Director to award at least five grants, annually, for each of the following: (1) integrated, multi-project research programs related to mitochondrial medicine; and (2) planning activities associated with such programs.

Authorizes the Director to award grants to institutions or consortiums of institutions to establish Mitochondrial Medicine Centers of Excellence to promote interdisciplinary research and training related to mitochondrial medicine.

Requires the Director to establish: (1) a national registry for the maintenance and sharing for research purposes of medical information collected from patients with mitochondrial disease or dysfunction; and (2) a national biorepository for the maintenance and sharing for research purposes of tissues and DNA collected from such patients.